Separate and Combined Extrapancreatic Effects of Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1

Registration

Registration

NCT05177653

Acronym

GA-19

Study type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Status

COMPLETED

Enrollment

13

Start

2022-04-07

Primary completion

2023-03-03

Lead sponsor

University Hospital, Gentofte, Copenhagen

Conditions

Pancreatectomy; Hyperglycemia

Interventions

OTHER:Intravenous infusion

Results posted

FALSE

Individual participant data sharing

NO

Registered primary outcomes

• Changes in plasma levels of glucose between interventions assessed through frequently blood sampling during the experimental days [Up to two months]
• Changes in plasma levels of glucagon (gut-derived) between interventions assessed through frequently blood sampling during the experimental days [Up to two months]
• Changes in plasma levels of insulin/C-peptide between interventions assessed through frequently blood sampling during the experimental days [Up to two months]
• Changes in plasma triglycerides between interventions assessed through frequently blood sampling during the experimental days. [Up to two months]
• Changes in plasma lipoproteins between interventions assessed through frequently blood sampling during the experimental days. [Up to two months]
• Changes in brown adipose tissue activity between interventions, assessed by thermographic camera [Up to two months]
• Changes in adiponectin in plasma between interventions, assessed through frequently blood sampling during the experimental days. [Up to two months]
• Changes in CTX between interventions assessed through frequently blood sampling during the experimental days [Up to two months]
• Changes in plasma P1NP between interventions assessed through frequently blood sampling during the experimental days [Up to two months]